We are live on
!
Find out more
Qube Research & Technologies (QRT) Portfolio holdings
AUM
$89.9B
1-Year Est. Return
20.22%
This Fund
S&P 500
This Quarter
Est. Return
+6.68%
1 Year Est. Return
+20.22%
3 Year Est. Return
+42.42%
5 Year Est. Return
+23.97%
10 Year Est. Return
–
AUM
$18.7B
AUM Growth
+$1.89B
(+11%)
Cap. Flow
+$1.31B
Cap. Flow
% of AUM
7.02%
Top 10 Holdings %
Top 10 Hldgs %
10.01%
Holding
3,237
New
779
Increased
845
Reduced
690
Closed
834
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$109M |
| 2 |
Norwegian Cruise Line
NCLH
|
+$105M |
| 3 |
Goldman Sachs
GS
|
+$104M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$101M |
| 5 |
Steel Dynamics
STLD
|
+$99.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Chevron
CVX
|
+$176M |
| 2 |
Coca-Cola
KO
|
+$151M |
| 3 |
Broadcom
AVGO
|
+$146M |
| 4 |
Microsoft
MSFT
|
+$140M |
| 5 |
ExxonMobil
XOM
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.93% |
| 2 | Industrials | 11.65% |
| 3 | Consumer Discretionary | 11.56% |
| 4 | Healthcare | 11.56% |
| 5 | Financials | 11.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
Xtrackers Harvest CSI 300 China A-Shares ETF
ASHR
$1.53B
| $820K | ﹤0.01% |
+29,280
| New | +$797K |
|
1302
First Trust Capital Strength ETF
FTCS
$8.03B
| $819K | ﹤0.01% |
+10,928
| New | +$806K |
|
1303
Opendoor
OPEN
$3.82B
| $817K | ﹤0.01% |
727,968
-1,270,302
| -64% | -$2.44M |
|
1304
iShares US Aerospace & Defense ETF
ITA
$14.5B
| $817K | ﹤0.01% |
7,301
+1,925
| +36% | +$205K |
|
|
BRMK
1305
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
| $816K | ﹤0.01% |
229,294
+70,717
| +45% | +$329K |
|
1306
Fomento Económico Mexicano
FMX
$43.5B
| $815K | ﹤0.01% |
10,438
+6,398
| +158% | +$471K |
|
1307
Global X Cybersecurity ETF
BUG
$1.26B
| $813K | ﹤0.01% |
39,179
+33,147
| +550% | +$764K |
|
1308
John Wiley & Sons Class A
WLY
$2.77B
| $811K | ﹤0.01% |
20,238
+6,785
| +50% | +$284K |
|
1309
CVB Financial
CVBF
$4.02B
| $811K | ﹤0.01% |
31,484
-56,089
| -64% | -$1.53M |
|
1310
NeoGenomics
NEO
$1.73B
| $807K | ﹤0.01% |
+87,337
| New | +$814K |
|
1311
O-I Glass
OI
$1.39B
| $806K | ﹤0.01% |
+48,648
| New | +$784K |
|
1312
Alkermes
ALKS
$8.47B
| $802K | ﹤0.01% |
30,680
+6,846
| +29% | +$164K |
|
1313
First Majestic Silver
AG
$7.74B
| $801K | ﹤0.01% |
96,026
-15,017
| -14% | -$131K |
|
1314
Upbound Group
UPBD
$1.25B
| $799K | ﹤0.01% |
35,433
+19,038
| +116% | +$408K |
|
|
USER
1315
DELISTED
UserTesting, Inc.
USER
| $798K | ﹤0.01% |
+106,194
| New | +$679K |
|
1316
iShares MSCI Saudi Arabia ETF
KSA
$622M
| $796K | ﹤0.01% |
21,116
+9,378
| +80% | +$379K |
|
1317
Warby Parker
WRBY
$3.17B
| $792K | ﹤0.01% |
+58,678
| New | +$897K |
|
|
BTX
1318
BlackRock Technology and Private Equity Term Trust
BTX
$914M
| $790K | ﹤0.01% |
+115,955
| New | +$827K |
|
1319
Marqeta
MQ
$1.91B
| $789K | ﹤0.01% |
+32,271
| New | +$881K |
|
|
BNFT
1320
DELISTED
Benefitfocus, Inc.
BNFT
| $787K | ﹤0.01% |
+75,252
| New | +$676K |
|
1321
KBR
KBR
$4.75B
| $786K | ﹤0.01% |
14,885
-598,384
| -98% | -$29.8M |
|
|
FOLD
1322
DELISTED
Amicus Therapeutics
FOLD
| $785K | ﹤0.01% |
64,290
-5,779
| -8% | -$65.1K |
|
1323
LSB Industries
LXU
$826M
| $781K | ﹤0.01% |
58,714
+15,264
| +35% | +$228K |
|
1324
GDS Holdings
GDS
$6.12B
| $780K | ﹤0.01% |
37,811
-290,179
| -88% | -$4.44M |
|
|
PETQ
1325
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $779K | ﹤0.01% |
84,469
-57,795
| -41% | -$540K |
|
Similar funds
Qube Research & Technologies (QRT)'s Q4 2022 Portfolio in Review
As of Q4 2022, Qube Research & Technologies (QRT) held 3,237 positions worth $18.7B, up 11% from $16.8B the previous quarter. Its ten largest holdings account for 10% of the portfolio.
Qube Research & Technologies (QRT) deployed $1.31B of net new capital in Q4 2022, opening 779 new positions and adding to 845 existing holdings. Its largest new stake was Bristol-Myers Squibb: 1,451,017 shares worth $104M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, down from 21% a quarter earlier, followed by Industrials and Consumer Discretionary.
On the sell side, the largest reduction was Microsoft, an estimated $140M trimmed.
- Qube Research & Technologies (QRT)'s largest Q4 2022 buy was Bristol-Myers Squibb: 1,451,017 shares worth $104M.
- Qube Research & Technologies (QRT) added most to Goldman Sachs in Q4 2022, an estimated $104M increase.
- Qube Research & Technologies (QRT)'s biggest Q4 2022 reduction was Microsoft, cutting an estimated $140M.
- Qube Research & Technologies (QRT) fully exited Chevron in Q4 2022, selling an estimated $176M.
- Qube Research & Technologies (QRT)'s ten largest holdings make up 10% of its $18.7B portfolio in Q4 2022.
- Qube Research & Technologies (QRT) opened 779 new positions and closed 834 in Q4 2022.
- Qube Research & Technologies (QRT)'s portfolio value rose 11% quarter-over-quarter to $18.7B.
Based on Qube Research & Technologies (QRT)'s 13F filing for Q4 2022, filed 14 Feb 2023.